172 related articles for article (PubMed ID: 2424286)
41. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
42. Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide).
Boritzki TJ; Berry DA; Besserer JA; Cook PD; Fry DW; Leopold WR; Jackson RC
Biochem Pharmacol; 1985 Apr; 34(7):1109-14. PubMed ID: 3985993
[TBL] [Abstract][Full Text] [Related]
43. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
[TBL] [Abstract][Full Text] [Related]
44. Antitumor activity of tiazofurin in human colon carcinoma HT-29.
Zhen W; Jayaram HN; Weber G
Cancer Invest; 1992; 10(6):505-11. PubMed ID: 1358409
[TBL] [Abstract][Full Text] [Related]
45. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
Szekeres T; Fritzer M; Pillwein K; Felzmann T; Chiba P
Life Sci; 1992; 51(16):1309-15. PubMed ID: 1357518
[TBL] [Abstract][Full Text] [Related]
46. Mode of action of 2-amino-6-chloro-1-deazapurine.
Bennett LL; Smithers D; Rose LM; Adamson DJ; Brockman RW
Biochem Pharmacol; 1984 Jan; 33(2):261-71. PubMed ID: 6142712
[TBL] [Abstract][Full Text] [Related]
47. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.
Olah E; Natsumeda Y; Ikegami T; Kote Z; Horanyi M; Szelenyi J; Paulik E; Kremmer T; Hollan SR; Sugar J
Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6533-7. PubMed ID: 2901100
[TBL] [Abstract][Full Text] [Related]
48. Recovery of the activities of IMP dehydrogenase and GMP synthase after treatment with tiazofurin and acivicin in hepatoma cells in vitro.
Ikegami T; Natsumeda Y; Weber G
Adv Exp Med Biol; 1989; 253B():299-304. PubMed ID: 2575350
[No Abstract] [Full Text] [Related]
49. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
[TBL] [Abstract][Full Text] [Related]
50. Tiazofurin action in leukemia: evidence for down-regulation of oncogenes and synergism with retinoic acid.
Weber G; Yamaji Y; Nagai M; Natsumeda Y; Jayaram HN; Zhen WN; Paulik E
Adv Enzyme Regul; 1990; 30():35-45. PubMed ID: 2206022
[TBL] [Abstract][Full Text] [Related]
51. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
Vitale M; Zamai L; Falcieri E; Zauli G; Gobbi P; Santi S; Cinti C; Weber G
Cytometry; 1997 Feb; 30(1):61-6. PubMed ID: 9056744
[TBL] [Abstract][Full Text] [Related]
52. Involvement of guanine nucleotides in superoxide release by fluoride-treated neutrophils. Implications for a role of a guanine nucleotide regulatory protein.
English D; Rizzo MT; Tricot G; Hoffman R
J Immunol; 1989 Sep; 143(5):1685-91. PubMed ID: 2547872
[TBL] [Abstract][Full Text] [Related]
53. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
54. Salvage capacity of hepatoma 3924A and action of dipyridamole.
Weber G; Lui MS; Natsumeda Y; Faderan MA
Adv Enzyme Regul; 1983; 21():53-69. PubMed ID: 6443595
[TBL] [Abstract][Full Text] [Related]
55. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.
Balzarini J; Karlsson A; Wang L; Bohman C; Horská K; Votruba I; Fridland A; Van Aerschot A; Herdewijn P; De Clercq E
J Biol Chem; 1993 Nov; 268(33):24591-8. PubMed ID: 7901217
[TBL] [Abstract][Full Text] [Related]
56. The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin.
Robins RK; Revankar GR; McKernan PA; Murray BK; Kirsi JJ; North JA
Adv Enzyme Regul; 1985; 24():29-43. PubMed ID: 2872781
[TBL] [Abstract][Full Text] [Related]
57. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
58. Regulation of de novo and salvage pathways in chemotherapy.
Weber G; Nagai M; Natsumeda Y; Ichikawa S; Nakamura H; Eble JN; Jayaram HN; Zhen WN; Paulik E; Hoffman R
Adv Enzyme Regul; 1991; 31():45-67. PubMed ID: 1877399
[TBL] [Abstract][Full Text] [Related]
59. Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines.
Szekeres T; Schuchter K; Chiba P; Ressmann G; Lhotka C; Gharehbaghi K; Szalay SM; Pillwein K
Biochem Pharmacol; 1993 Dec; 46(11):1903-7. PubMed ID: 7903533
[TBL] [Abstract][Full Text] [Related]
60. Tiazofurin: biological effects and clinical uses.
Tricot G; Jayaram HN; Weber G; Hoffman R
Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
